Furthermore, the report also mentioned that IBD patients receiving anti-TNF therapy combined with immunomodulators had worse outcomes, with 40.9% achieving levels adequate for protection (P < 0.001) (24). The gene discussed is TNF; the disease is inflammatory bowel disease.